Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Baylor College of Medicine, U.S.
Transduction of cytotoxic T lymphocytes may be safe for cancer treatment
July 4th, 2006
A study from the United States has reported on the safety assessment of cytotoxic T lymphocytes (CTLs) transduced with a dominant negative transforming growth factor (TGF)-beta receptor (DNR). "TGF-beta, a pleiotropic cytokine that regulates cell growth. is secreted by many human tumors and markedly inhibits tumor-specific cellular immunity. It has previously been shown by our group that transduction of CTLs with a retroviral vector expressing the DNR overcomes this tumor evasion in a model of Epstein-Barr virus (EBV)-positive Hodgkin disease," wrote K. Lacuesta and colleagues, Baylor College of Medicine. They continued, "TGF beta is an important...
Source: Pharma Law Weekly (2006-07-04)
|
